middle.news
BCAL Diagnostics Details Convertible Note Drawdowns and Shareholder Approval Timeline
6:14pm on Friday 21st of August, 2026 AEST
•
Healthcare
Read Story
BCAL Diagnostics Details Convertible Note Drawdowns and Shareholder Approval Timeline
6:14pm on Friday 21st of August, 2026 AEST
Key Points
Convertible note facility of $10 million approved in November 2025
Issued $3.1 million in notes within initial three months ending February 2026
Additional $4.5 million drawn since then with planned drawdowns subject to approval
Notes carry 10% annual interest, convertible into shares at a discounted price
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bcal Diagnostics (ASX:BDX)
OPEN ARTICLE